The Japanese New Drug Application refers to the application for the approval of a new medicinal product in the Japanese market. The Pharmaceuticals and Medical Devices Agency, PMDA, reviews data on quality, safety and efficacy and supports development through a structured consultation system. The term refers to the Japanese procedure and must not be confused with the New Drug Application of the US FDA.<\/p>\n
In Japan, the PMDA is responsible for reviews, consultations, conformity assessments and inspections in the field of medicinal products and other medical products. For new medicinal products, it reviews the regulatory usability of development and submission data. An application for approval must document the product, its manufacture, the nonclinical and clinical evidence, and the intended use in such a way that quality, efficacy and safety can be assessed. Electronic study data can be submitted via the designated gateway system and are subject to validation rules.<\/p>\n
The submission strategy should therefore not be developed only at the end of development. Data formats, the traceability of analyses, the quality of source documentation and the rationale for clinical decisions influence the subsequent reviewability. The PMDA uses electronic data for reviews and consultations to support evidence-based assessments. The requirements may differ depending on the product type and development program; an international dossier structure alone does not replace consideration of Japanese expectations.<\/p>\n
A defining element of the Japanese procedure is the PMDA consultations. They provide guidance on clinical trials and on data for regulatory submissions. In consultations on new medicinal products, the PMDA assesses whether a proposed trial program is compatible with the requirements for a subsequent submission. In doing so, it considers ethical and scientific aspects, the reliability of the study and the safety of study participants.<\/p>\n
In addition to preparatory discussions, consultations are available for different development phases and topics. Pre-assessment consultations enable PMDA reviewers to assess data on quality, efficacy and safety even before submission. After the application has been submitted, this consultation process may become part of the product review. The consultation system is therefore not an informal substitute for the application, but an instrument for clarifying questions concerning the development and submission plan at an early stage and for planning evidence generation in a targeted manner.<\/p>\n
Global data may be relevant to a Japanese New Drug Application, but their transferability to the Japanese population must be assessed. ICH E5 addresses ethnic factors in the acceptance of foreign clinical data. The guideline distinguishes intrinsic factors of the recipient of the medicinal product and extrinsic factors arising from the environment and culture that may influence study results in different regions. A Bridging Study may be requested to clarify whether data from one region are applicable in a new region.<\/p>\n
Bridging does not automatically mean that a complete repetition of a global program in Japan is required. The strategy depends on the product, pharmacokinetics, dose-response relationship, endpoints and the available evidence. ICH E17 complements this perspective with general principles for the planning and design of multiregional clinical trials. If regional factors and the inclusion of Japanese centers are considered at an early stage, a multiregional study can support the subsequent assessment. However, it does not replace the product-specific regulatory review by the PMDA.<\/p>\n
The US New Drug Application is an application to the FDA under the Federal Food, Drug, and Cosmetic Act and the regulations in 21 CFR Part 314. The Japanese New Drug Application is submitted under the Japanese legal and regulatory framework. Both procedures may contain similar scientific components, such as clinical efficacy and safety data or a structured dossier, but they involve different authorities, consultation systems and legal consequences.<\/p>\n
A US NDA under Section 505(b)(1) or 505(b)(2), an ANDA and a BLA are types of applications under US law. They are not equivalent to the Japanese designation. Conversely, successful interaction with the FDA does not establish Japanese marketing authorization status. For global programs, it is therefore necessary to plan the requirements of the FDA and PMDA separately while scientifically and regulatorily justifying the possible use of common data.<\/p>\n
For a Japanese development program, study protocols, data flows and statistical analyses must be designed to make the transferability of the evidence and local regulatory acceptability comprehensible. Early consultations can clarify questions concerning the population, dosage, development stage and electronic submission data. Operationally, robust data standards, consistent safety data and a documented rationale for the regional strategy are particularly important.<\/p>\n
Full-service CROs such as Mediconomics support the planning of multiregional studies, project management, trial site management, monitoring, data management, biostatistics, pharmacovigilance and medical writing. They can coordinate the preparation of consultation documents and the integration of global clinical data with local requirements so that the evidence base for a Japanese New Drug Application is comprehensible and submission-ready.<\/p>\n
Does a US NDA replace Japanese marketing authorization?<\/strong><\/p>\n No. The US NDA and the Japanese New Drug Application belong to different legal systems and regulatory procedures.<\/p>\n What is the benefit of a PMDA consultation?<\/strong><\/p>\n It provides guidance on studies and submission data before the application for approval is submitted and supports targeted development planning.<\/p>\n Is a Bridging Study always required?<\/strong><\/p>\n No. It is one possible strategy under ICH E5 when the transferability of foreign data to a new region must be assessed.<\/p>\n The Japanese New Drug Application refers to the application for the approval of a new medicinal product in the Japanese market. The Pharmaceuticals and Medical Devices Agency, PMDA, reviews data on quality, safety and efficacy and supports development through a structured consultation system. The term refers to the Japanese procedure and must not be confused […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6672","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6672\/revisions"}],"predecessor-version":[{"id":7492,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6672\/revisions\/7492"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6672"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n